Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $65.44 Consensus Target Price from Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been given an average rating of "Buy" by the ten research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $65.44.

A number of analysts recently issued reports on VERA shares. JPMorgan Chase & Co. raised their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Guggenheim raised their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a research note on Monday, October 28th. The Goldman Sachs Group began coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price objective on the stock. Wells Fargo & Company assumed coverage on Vera Therapeutics in a report on Thursday, November 21st. They set an "overweight" rating and a $70.00 price objective for the company. Finally, Wolfe Research assumed coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock.

Insider Activity

In other news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now owns 143,603 shares in the company, valued at approximately $5,993,989.22. This trade represents a 10.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 52,500 shares of company stock worth $2,305,625 in the last three months. Corporate insiders own 21.70% of the company's stock.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VERA. Huntington National Bank bought a new position in shares of Vera Therapeutics in the 4th quarter worth $26,000. AlphaQuest LLC purchased a new position in Vera Therapeutics in the fourth quarter worth $34,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock valued at $86,000 after acquiring an additional 350 shares during the last quarter. KBC Group NV raised its position in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after purchasing an additional 1,387 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Performance

NASDAQ:VERA traded up $0.32 during trading on Friday, reaching $27.78. The company's stock had a trading volume of 685,342 shares, compared to its average volume of 859,251. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -10.60 and a beta of 1.11. Vera Therapeutics has a 12 month low of $25.99 and a 12 month high of $51.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm has a 50 day moving average of $38.51 and a 200-day moving average of $40.85.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.